CMPX News

Latest breaking news and updates for CMPX stock.

Track all markets on TradingView

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

How might the market interpret the need for a $120 million raise—does it signal cash‑flow constraints, accelerated development plans, or strategic expansion? What potential impact could the warrant over‑hang have on the stock price if the warrants are exercised in the near term? Will the increased float from this offering improve liquidity and reduce bid‑ask spreads for CMPX shares?
Capital raise
16 days ago
Read more globenewswire

Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutic...

How might the disclosed results affect the risk/reward profile for existing and prospective investors in CMPX? What potential partnership, licensing, or acquisition activities were hinted at in the corporate update? Did the company provide guidance for Q3 2025 or the full‑year 2025, and how reliable is that guidance given historical performance?
Earnings
18 days ago
Read more globenewswire

Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutic...

What is the competitive landscape for the indications targeted by tovecimig, CTX‑8371, and CTX‑10726, and how does Compass Therapeutics differentiate its assets? Did the company address any potential regulatory challenges or FDA interactions related to the tovecimig program? What is the anticipated impact of these updates on the stock price in the short term (e.g., intraday volatility) and long term (e.g., growth trajectory)?
Earnings
20 days ago
Read more globenewswire